Table 2

Sample proportions for testing and treatment outcomes and behaviour for N=444 study participants by study group

Group A: ACT subsidy and RDT subsidy
N=116
Group B: RDT subsidy
N=107
Group C: ACT subsidy
N=114
Group D: no subsidy (reference) N=107Total
N=444
%%%%%
Had a malaria test*73.7 (n=84)73.8 (n=76)49.6 (n=56)51.0 (n=51)62.1 (n=267)
 Positive39.3 (n=33)27.6 (n=21)44.6 (n=25)47.1 (n=24)38.6 (n=103)
  No ACT18.228.616.041.725.2
  ACT81.871.484.058.374.8
 Negative60.7 (n=51)72.4 (n=55)55.4 (n=31)52.9 (n=27)61.4 (n=164)
  No ACT72.580.087.192.681.1
  ACT27.520.012.97.418.9
 Appropriate ACT use†76.2 (n=84)77.6 (n=76)85.7 (n=56)76.5 (n=51)78.7 (n=267)
Did not have a test26.3 (n=30)26.2 (n=27)50.4 (n=57)49.0 (n=49)37.9 (n=163)
 No ACT70.070.478.973.574.2
 ACT30.029.621.126.525.8
Targeted ACT use‡56.1 (n=116)57.3 (n=107)42.5 (n=114)39.0 (n=107)48.8 (n=444)
ObservationsN=114N=103N=113N=100N=430
  • *Self-report of any malaria test (RDT or slide) at health facility or tested by the CHW.

  • †Defined as taking ACT if positive or not taking ACT if negative among those who had a malaria test.

  • ‡Defined as taking ACT if positive or not taking ACT if negative among all participants.

  • ACT, artemisinin combination therapy; RDT, rapid diagnostic test.